Alpha-1-antitrypsin (AAT) is a glycoprotein produced by liver cells and secreted into the serum (Laurell & Jeppsson, 1975) . Since AAT can inactivate a wide variety of proteolytic enzymes such as pancreatic and leukocyte elastase, trypsin, chymotrypsin, collagenase, plasmin and thrombin, it is considered to be important in regulating a variety of proteolytic and thromboplastic processes on both systemic and local levels (Rimon et al., 1966; Eisen et al., 1970; Koj et al., 1972; Beatty et al., 1980) . AAT is expressed not only in normal livers but also in other normal tissues such as the lung, gall bladder, pancreas, and the gastrointestinal tract (Tuttle & Jones, 1975; Ray et al., 1978; Kittas et al., 1982a; Geboes et al., 1982; Tahara et al., 1984; Aroni et al., 1984) . Moreover, AAT has also been demonstrated in several neoplasms including carcinomas, mesenchymal tumours, hemopoietic and brain tumours (Reintoft & Hargerstrand, 1979; Kittas et al., 1982b; Glasgow et al., 1982; Aroni et al., 1984; Tahara et al., 1984; Krugliak et al., 1986; Wittekind et al., 1986; Sawaya et al., 1987; Soini & Miettinen, 1989; Kataoka et al., 1989; Perlmutter et al., 1989; Karashima et al., 1990) . The presence of AAT in tumour cells is now considered to be due to its production by tumour cells themselves (Glasgow et al., 1982; Perlmutter et al., 1989; Kataoka et al., 1989) . However, its significance in neoplastic tissues remains unknown.
Recently, with few exceptions, several reports have shown that cases with AAT expression in tumour cells had worse prognosis than those without AAT expression, suggesting that AAT production in tumours cells may correlate with more aggressive behaviour in some gastrointestinal cancers (Tahara et al., 1984; Wittekind et al., 1986; Karashima et al., 1990) .
AAT expression in lung cancer has not been studied yet. Therefore, in order to clarify the clinicopathological significance of AAT expression in lung cancer, the authors performed a preliminary immunohistochemical study of its incidence in lung adenocarcinoma. Immunohistochemistry was performed according to a modified method of Hsu et al. (1981) . Briefly, sections (4 tim thick) were deparaffinised, and endogenous peroxidase activity was blocked using 0.3% hydrogen peroxide in methanol.
Materials and methods

Formalin
After immersion in 2% normal goat serum, the sections were incubated with specific rabbit antisera overnight at 4'C, and subsequently with biotinylated goat-rabbit IgG (Vector) and avidin-biotin peroxidase complex (Vectastain ABC kit, Vector) for 30min each at room temperature. The peroxidase reaction used 0.02% 3,3'-diaminobenzidine tetrahydrochloride in 0.05 M TRIS buffer, pH 7.6, containing 0.01% hydrogen peroxide. Sections were counterstained with Mayer's haematoxylin. In all specimens, serum in blood vessels or some macrophages was used as an internal positive control for AAT immunoperoxidase staining, while normal rabbit serum was used for negative controls. Anti-AAT antiserum purchased from Dakopatts, Denmark, was used at a dilution of 1:300. Specificity of the antiserum was confirmed as described by Tahara et al. (1984) and Karashima et al. (1990) .
Staining results were evaluated semi-quantitatively, taking into account the percentage of AAT-positive tumour cells within tumour tissues [<1% = negative (-), 1-80% = weak-to-moderately positive ( + ), 80% < = strongly positive (+ +)]. The Kaplan-Meier method was used to calculate postoperative survival rate, and prognostic significance was evaluated by the generalised Wilcoxon test. The chi-square test was used for further statistical analysis. P<0.05 was considered to be significantly different.
Results
Eighty-nine cases (87%) of primary adenocarcinoma expressed AAT in tumour cells, admixed with AAT-positive and -negative tumour cells in varying degrees within the tumour tissues ( Figure 1 , Table I ). Only 13 patients (13%) were negative for AAT expression in tumour cells. weak-to-moderately AAT-positive cases and 35% in strongly AAT-positive cases. According to the generalised Wilcoxon test, statistical differences were observed between strongly AAT-positives and AAT-negatives (P<0.05), and between strongly AAT-positives and weak-to-moderately AAT-positives (P<0.01).
Discussion
AAT expression in tumour cells of the digestive system has been immunohistochemically studied (Reintoft & Hagerstrand, 1979; Kittas et al., 1982b; Tahara et al., 1984; Aroni et al., 1984; Wittekind et al., 1986; Karashima et al., 1990) . In colorectal cancer, Karashima et al. (1990) reported that the incidence of AAT expression was markedly higher in advanced cases than in early cases, and that AAT-positive cases had a poor prognosis than AAT-negative cases, particularly in early stages. Tahara et al. (1984) reported similar findings in gastric cancer. Our results showed that AAT expression in tumour cells of lung adenocarcinoma is also strongly associated with tumour growth and prognosis. However, according to the balance between proteolytic and its inhibitory activities in tumour cells, these results are apparently inconsistent with previous reports that high activity of proteolytic enzymes, e.g. serine proteases, in tumour cells is associated with malignant potency (Mignatti et al., 1986; Tryggvason et al., 1987; Zucker, 1988 Ades et al., 1982) . Sawaya et al. (1987) suggested that AAT produced in brain tumours may protect against inflammatory activity of the host. Therefore, AAT in tumour cells may have the capacity to promote tumour development and metastasis by incapacitating host anti-tumour defense mechanisms. Secondly, McKeehan et al. (1986) found that AAT may exhibit growth-stimulating activities on endothelial cells, maintaining blood circulation within tumour tissues for tumour development. Thirdly, AAT may act as a proteolytic enzyme 'carrier' rather than as an 'inhibitor' (Beatty et al., 1982) . Karashima et al. (1990) speculated that the protease-AAT complex may dissociate in the presence of suitable substrate and degrade extracellular matrices by releasing proteolytic protease.
In conclusion, although further study will be required to elucidate the mechanism and role of AAT expression in lung adenocarcinoma, we confirmed that strongly AAT-positive lung adenocarcinomas was characterised by its high malignancy and poor prognosis. Our results indicate that AAT expression may be a biological marker of potential prognostic significance, particularly in early cases of lung adenocarcinoma.
